Laura Bau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Laura Bau has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Elisabet Matas
Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
7 shared publications - Lucía Romero-Pinel
Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
7 shared publications - Sergio Martínez-Yélamos
Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
7 shared publications - Albert Muñoz-Vendrell
Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
5 shared publications - Antonio Martínez-Yélamos
Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
5 shared publications - Isabel León
Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
5 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Springer Nature in BMC Neurology
Aetiologic spectrum of longitudinally extensive spinal cord lesions and clues to their differential diagnosis
- 3 November 2026
- Published by Springer Nature in BMC Neurology
Open AccessAetiologic spectrum of longitudinally extensive spinal cord lesions and clues to their differential diagnosis
- Open Access
- 22 June 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (7)
Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis
Background: Subcutaneous natalizumab offers greater convenience than intravenous administration, but pharmacokinetic differences have raised concerns about potential subclinical disease activity. Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) are sensitive biomarkers of neuroaxonal damage and astroglial activation. Methods: In this prospective, single-center cohort study, consecutive patients with relapsing–remitting multiple sclerosis who transitioned from intravenous to subcutaneous natalizumab were followed for 12 months. Serum sNfL and GFAP were measured at baseline (prior to switch), and at 6 and 12 months using SIMOA technology. Additional clinical outcomes included annualized relapse rate (ARR), EDSS, and MRI activity. Results: 23 patients were included (mean age 43.7 years; 91% female). Median disease duration was 14 years (IQR 8.1–22), median time on natalizumab was 5 years (IQR 3.3–7.9), baseline 2-year ARR was 0.09 ± 0.2, and median EDSS was 2.0 (IQR 2.0–3.5). Median sNfL Z -scores were 0.2 (IQR − 0.3–0.6) at baseline, 0.1 (IQR − 0.4–1.0) at 6 months, and 0.5 (IQR − 0.4–1.1) at 12 months, with no significant change over time ( p = 0.401). GFAP levels were similarly stable (87.7, 86.8, and 90.2 pg/mL; p = 0.957). ARR remained low and unchanged (0.09 pre- and post-switch; p = 1.0), with no radiological activity observed. EDSS remained stable over follow-up. Conclusions: In this small real-world cohort, switching from intravenous to subcutaneous natalizumab was associated with stable sNfL and GFAP levels over 12 months, alongside stable conventional clinical and MRI outcomes. These findings provide supplementary biomarker evidence broadly consistent with existing clinical trial and real-world data, but should be interpreted cautiously given the small sample size.
- 22 June 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (7)
Open AccessSerum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis
Background: Subcutaneous natalizumab offers greater convenience than intravenous administration, but pharmacokinetic differences have raised concerns about potential subclinical disease activity. Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) are sensitive biomarkers of neuroaxonal damage and astroglial activation. Methods: In this prospective, single-center cohort study, consecutive patients with relapsing–remitting multiple sclerosis who transitioned from intravenous to subcutaneous natalizumab were followed for 12 months. Serum sNfL and GFAP were measured at baseline (prior to switch), and at 6 and 12 months using SIMOA technology. Additional clinical outcomes included annualized relapse rate (ARR), EDSS, and MRI activity. Results: 23 patients were included (mean age 43.7 years; 91% female). Median disease duration was 14 years (IQR 8.1–22), median time on natalizumab was 5 years (IQR 3.3–7.9), baseline 2-year ARR was 0.09 ± 0.2, and median EDSS was 2.0 (IQR 2.0–3.5). Median sNfL Z -scores were 0.2 (IQR − 0.3–0.6) at baseline, 0.1 (IQR − 0.4–1.0) at 6 months, and 0.5 (IQR − 0.4–1.1) at 12 months, with no significant change over time ( p = 0.401). GFAP levels were similarly stable (87.7, 86.8, and 90.2 pg/mL; p = 0.957). ARR remained low and unchanged (0.09 pre- and post-switch; p = 1.0), with no radiological activity observed. EDSS remained stable over follow-up. Conclusions: In this small real-world cohort, switching from intravenous to subcutaneous natalizumab was associated with stable sNfL and GFAP levels over 12 months, alongside stable conventional clinical and MRI outcomes. These findings provide supplementary biomarker evidence broadly consistent with existing clinical trial and real-world data, but should be interpreted cautiously given the small sample size.
- Open Access
- 5 November 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (11) , 1-9
Benign multiple sclerosis and long-term outcomes after 30 years
Background: The concept of benign multiple sclerosis (MS) is a matter of debate. In most definitions, only the Expanded Disability Status Scale (EDSS) score and disease duration are considered, although other factors may influence a patient’s disability. The aims of this study were to evaluate the percentage of patients with benign MS in our cohort and to determine the proportion of these patients who remained benign after 20 and 30 years of disease evolution. Clinical and demographic variables related to this outcome were investigated. Methods: Patients fulfilling the criteria for benign MS (EDSS < 3.0 and at least 10 years of MS evolution) were selected from a hospital-based series and followed up prospectively. The EDSS was assessed after 20 and 30 years of MS evolution. Clinical and radiological variables were evaluated. Fatigue, depression and cognition tests were performed. Results: Eighty-two of the 485 patients evaluated in 1996 fulfilled the criteria for benign MS and were selected. In 51 of the 68 (75%) patients evaluated in 2006, the EDSS score continued to be ≤ 3. In 2016, 35 out of 58 (60%) patients continued to have an EDSS score ≤ 3. None of the clinical variables could predict persistence in the benign group. Eighteen of the 35 benign MS patients completed the questionnaires after 30 years. Fifty percent of them reported fatigue, 22% depression, and 83% had cognitive impairment. Conclusion: The majority of MS patients maintained a benign status even after 30 years of disease evolution. However, cognitive impairment in this group is notable.
- 5 November 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (11) , 1-9
Open AccessBenign multiple sclerosis and long-term outcomes after 30 years
Background: The concept of benign multiple sclerosis (MS) is a matter of debate. In most definitions, only the Expanded Disability Status Scale (EDSS) score and disease duration are considered, although other factors may influence a patient’s disability. The aims of this study were to evaluate the percentage of patients with benign MS in our cohort and to determine the proportion of these patients who remained benign after 20 and 30 years of disease evolution. Clinical and demographic variables related to this outcome were investigated. Methods: Patients fulfilling the criteria for benign MS (EDSS < 3.0 and at least 10 years of MS evolution) were selected from a hospital-based series and followed up prospectively. The EDSS was assessed after 20 and 30 years of MS evolution. Clinical and radiological variables were evaluated. Fatigue, depression and cognition tests were performed. Results: Eighty-two of the 485 patients evaluated in 1996 fulfilled the criteria for benign MS and were selected. In 51 of the 68 (75%) patients evaluated in 2006, the EDSS score continued to be ≤ 3. In 2016, 35 out of 58 (60%) patients continued to have an EDSS score ≤ 3. None of the clinical variables could predict persistence in the benign group. Eighteen of the 35 benign MS patients completed the questionnaires after 30 years. Fifty percent of them reported fatigue, 22% depression, and 83% had cognitive impairment. Conclusion: The majority of MS patients maintained a benign status even after 30 years of disease evolution. However, cognitive impairment in this group is notable.
- Open Access
- 29 July 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 103, 106658
The 2024 McDonald criteria show comparable sensitivity to previous criteria for late-onset multiple sclerosis
- 29 July 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 103, 106658
Open AccessThe 2024 McDonald criteria show comparable sensitivity to previous criteria for late-onset multiple sclerosis
- Open Access
- 17 September 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (1) , 335-342
Assessment of the Multiple Sclerosis Severity Score and the Age-Related Multiple Sclerosis Severity Score as health indicators in a population-based cohort
Background: People with multiple sclerosis (MS) present varying degrees of disability throughout their disease course. The Multiple Sclerosis Severity Score (MSSS) and the Age-Related Multiple Sclerosis Severity Score (ARMSSS) adjust the Expanded Disability Status Scale (EDSS) according to disease duration and age, respectively. These measures could be useful for quantifying MS severity and as health outcome indicators for benchmarking in population-based settings. The aim of this study was to describe the severity of MS in our health district using the MSSS and ARMSSS and to assess their consistency over time. Methods: This population-based study included patients from our health district who were diagnosed with MS according to the 2010 McDonald criteria, had a disease duration of at least one year and were followed up in our MS unit. Sex, age at onset, disease duration, clinical course, age and irreversible EDSS at the last follow-up visit were collected, and the MSSS and ARMSSS were calculated at two time points: 2017 and 2020. Results: One hundred seventy-seven patients were included in 2017, and 208 in 2020. The prevalence of MS was 90 and 104 per 100,000 inhabitants, respectively. The median MSSS was 1.77 (IQR 0.76–4.28) in 2017 and 2.03 (IQR 0.82–4.36) in 2020. The median ARMSSS was 2.90 (IQR 1.47–5.72) in 2017 and 2.93 (IQR 1.51–5.56) in 2020. No significant differences were found. Conclusions: According to the MSSS and ARMSSS, the severity of MS in our area is mild, and these instruments are consistent. These measures could be reliable health outcome measures.
- 17 September 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (1) , 335-342
Open AccessAssessment of the Multiple Sclerosis Severity Score and the Age-Related Multiple Sclerosis Severity Score as health indicators in a population-based cohort
Background: People with multiple sclerosis (MS) present varying degrees of disability throughout their disease course. The Multiple Sclerosis Severity Score (MSSS) and the Age-Related Multiple Sclerosis Severity Score (ARMSSS) adjust the Expanded Disability Status Scale (EDSS) according to disease duration and age, respectively. These measures could be useful for quantifying MS severity and as health outcome indicators for benchmarking in population-based settings. The aim of this study was to describe the severity of MS in our health district using the MSSS and ARMSSS and to assess their consistency over time. Methods: This population-based study included patients from our health district who were diagnosed with MS according to the 2010 McDonald criteria, had a disease duration of at least one year and were followed up in our MS unit. Sex, age at onset, disease duration, clinical course, age and irreversible EDSS at the last follow-up visit were collected, and the MSSS and ARMSSS were calculated at two time points: 2017 and 2020. Results: One hundred seventy-seven patients were included in 2017, and 208 in 2020. The prevalence of MS was 90 and 104 per 100,000 inhabitants, respectively. The median MSSS was 1.77 (IQR 0.76–4.28) in 2017 and 2.03 (IQR 0.82–4.36) in 2020. The median ARMSSS was 2.90 (IQR 1.47–5.72) in 2017 and 2.93 (IQR 1.51–5.56) in 2020. No significant differences were found. Conclusions: According to the MSSS and ARMSSS, the severity of MS in our area is mild, and these instruments are consistent. These measures could be reliable health outcome measures.
- 1 February 2016
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 291, 73-77
MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients
- 1 February 2016
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 291, 73-77
MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients
- 1 November 2011
- Published by Elsevier in Value in Health
- Vol. 14 (7) , A320
PND19 Cost Of The Relapse Of Multiple Sclerosis In Spain
- 1 November 2011
- Published by Elsevier in Value in Health
- Vol. 14 (7) , A320
PND19 Cost Of The Relapse Of Multiple Sclerosis In Spain